Blanca García Micó
@garciamicob
ID: 1590821441301356545
10-11-2022 21:40:10
20 Tweet
19 Followers
57 Following
🥇Un gran equipo liderado por Andres Cervantes dedicado 💯 a la lucha contra el cáncer gastrointestinal👊! Carola Mart-Ciarp Valentina Gambardella Francisco Gimeno-Valiente Jorge Martin Arana Marisol Aras Manuel Cabeza-Segura Tania Fleitas Kanonnikoff Elena Duréndez Desam Roda Blanca García Micó Arturo
👉 and super proud of my PhD students Blanca García Micó & Belén Martínez Castedo who presented part of our work and were awarded for the best case report 🥇
📌 Hazte SOCI@ de ASEICA ASEICA ❗️ 👩🏻🔬 Investigadores básicos y clínicos unidos 🤝 contra el cáncer. 👇Te esperamos en la comunidad ASEICA 😃 Marisol Soengas Luis Paz-Ares Rafael Lopez Miguel Fernández de Sanmamed Elena Castro 🗒️ aseica.es/hazte-socio
🔝It has been a pleasure to listen to Adrià Cañellas Socias at INCLIVA discussing the development of metastasis in CRC. 📌 Is it the time for immunotherapy in the localized setting … and when❓ Myriam Chalabi opened up a new scenario! ✔️A must-read 📄 nature.com/articles/s4158…
💥JUST OUT our latest paper in ESMO Open🩸 📌The potential value of a germline sequencing approach: ✔️ 100% patients could monitor MRD. ✔️Ethical implications for the patient and their family. ✔️Identify actionable alterations. Work supported by Kristof V Grupo Español de Tratamiento de Tumores Digestivos
📌 No te pierdas los nuevos conocimientos 🧠 en INMUNOTERAPIA de Miguel Fernández de Sanmamed en INCLIVA Hospital Clínic de València 🧑🏻🔬 Experto en inmunoterapia en Universidad de Navarra realizó su posdoc en la Universidad de Yale (EEUU) ASEICA 🏥 Mañana en INCLIVA Hospital Clínic de València 🖥️ También conexión por Teams👇
🚨 Just out in Annals of Oncology! 🌊 Dive into the latest on liquid biopsy for colorectal cancer🩸: What’s the best approach to monitor ctDNA? Tumor-informed vs. tumor-agnostic strategies for minimal residual disease detection. 📄Read here: [annalsofoncology.org/article/S0923-…]
🚨 Our latest study led by Carola Mart-Ciarp & Brenda Palomar introduces a tumor budding-stroma score to better predict risk in MSS-CC. 🚀A step forward in personalized treatment! 🔗 sciencedirect.com/science/articl…
🔥Just out in Nature Cancer! ✅ TAV16, our tumor-agnostic WES-based assay, ranks among the best for MRD detection. ✅ Immune evasion as the main driver progression in MSS CRC, opening new avenues for ICIs. 🙏SEOM Grupo Español de Tratamiento de Tumores Digestivos Instituto de Salud Carlos III (ISCIII) Hospital Clínic de València nature.com/articles/s4301…
💥Proud of our team for presenting cutting-edge work on ctDNA🩸and tumor-immune profiling in CRC at #EACR2025! 🔬From resistance mechanisms to new immunotherapy strategies - science made in Valencia INCLIVA 🇪🇸✨ 🔝Belén Martínez Castedo Daniel González Camblor Blanca García Micó
Very proud of this recognition and of the incredible team behind it! Honored to see our work featured on the cover of Nature Cancer
🤝An international collaboration with Aparna Raj Parikh and our CRC team INCLIVA GVA Sanitat